Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

Jeong Heo, Tony Reid, Leyo Ruo, Caroline J. Breitbach, Steven Rose, Mark Bloomston, Mong Cho, Ho Yeong Lim, Hyun Cheol Chung, Chang Won Kim, James Burke, Riccardo Lencioni, Theresa Hickman, Anne Moon, Yeon Sook Lee, Mi Kyeong Kim, Manijeh Daneshmand, Kara Dubois, Lara Longpre, Minhtran NgoCliona Rooney, John C. Bell, Byung Geon Rhee, Richard Patt, Tae Ho Hwang, David H. Kirn

Research output: Contribution to journalArticle

385 Citations (Scopus)

Abstract

Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in tumors, yet the impact of dose on subject outcome is unclear. JX-594 (Pexa-Vec) is an oncolytic and immunotherapeutic vaccinia virus. To determine the optimal JX-594 dose in subjects with advanced hepatocellular carcinoma (HCC), we conducted a randomized phase 2 dose-finding trial (n = 30). Radiologists infused low- or high-dose JX-594 into liver tumors (days 1, 15 and 29); infusions resulted in acute detectable intravascular JX-594 genomes. Objective intrahepatic Modified Response Evaluation Criteria in Solid Tumors (mRECIST) (15%) and Choi (62%) response rates and intrahepatic disease control (50%) were equivalent in injected and distant noninjected tumors at both doses. JX-594 replication and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression preceded the induction of anticancer immunity. In contrast to tumor response rate and immune endpoints, subject survival duration was significantly related to dose (median survival of 14.1 months compared to 6.7 months on the high and low dose, respectively; hazard ratio 0.39; P = 0.020). JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC.

Original languageEnglish
Pages (from-to)329-336
Number of pages8
JournalNature Medicine
Volume19
Issue number3
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Vaccinia
Liver Neoplasms
Liver
Tumors
Clinical Trials
Neoplasms
Hepatocellular Carcinoma
Viruses
Oncolytic Viruses
Vaccinia virus
Disease control
Granulocyte-Macrophage Colony-Stimulating Factor
Immunotherapy
Immunity
Genome
Hazards
Genes

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., ... Kirn, D. H. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nature Medicine, 19(3), 329-336. https://doi.org/10.1038/nm.3089
Heo, Jeong ; Reid, Tony ; Ruo, Leyo ; Breitbach, Caroline J. ; Rose, Steven ; Bloomston, Mark ; Cho, Mong ; Lim, Ho Yeong ; Chung, Hyun Cheol ; Kim, Chang Won ; Burke, James ; Lencioni, Riccardo ; Hickman, Theresa ; Moon, Anne ; Lee, Yeon Sook ; Kim, Mi Kyeong ; Daneshmand, Manijeh ; Dubois, Kara ; Longpre, Lara ; Ngo, Minhtran ; Rooney, Cliona ; Bell, John C. ; Rhee, Byung Geon ; Patt, Richard ; Hwang, Tae Ho ; Kirn, David H. / Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. In: Nature Medicine. 2013 ; Vol. 19, No. 3. pp. 329-336.
@article{a0b6e91e16454217b2e0a6502a665f3a,
title = "Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer",
abstract = "Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in tumors, yet the impact of dose on subject outcome is unclear. JX-594 (Pexa-Vec) is an oncolytic and immunotherapeutic vaccinia virus. To determine the optimal JX-594 dose in subjects with advanced hepatocellular carcinoma (HCC), we conducted a randomized phase 2 dose-finding trial (n = 30). Radiologists infused low- or high-dose JX-594 into liver tumors (days 1, 15 and 29); infusions resulted in acute detectable intravascular JX-594 genomes. Objective intrahepatic Modified Response Evaluation Criteria in Solid Tumors (mRECIST) (15{\%}) and Choi (62{\%}) response rates and intrahepatic disease control (50{\%}) were equivalent in injected and distant noninjected tumors at both doses. JX-594 replication and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression preceded the induction of anticancer immunity. In contrast to tumor response rate and immune endpoints, subject survival duration was significantly related to dose (median survival of 14.1 months compared to 6.7 months on the high and low dose, respectively; hazard ratio 0.39; P = 0.020). JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC.",
author = "Jeong Heo and Tony Reid and Leyo Ruo and Breitbach, {Caroline J.} and Steven Rose and Mark Bloomston and Mong Cho and Lim, {Ho Yeong} and Chung, {Hyun Cheol} and Kim, {Chang Won} and James Burke and Riccardo Lencioni and Theresa Hickman and Anne Moon and Lee, {Yeon Sook} and Kim, {Mi Kyeong} and Manijeh Daneshmand and Kara Dubois and Lara Longpre and Minhtran Ngo and Cliona Rooney and Bell, {John C.} and Rhee, {Byung Geon} and Richard Patt and Hwang, {Tae Ho} and Kirn, {David H.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1038/nm.3089",
language = "English",
volume = "19",
pages = "329--336",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "3",

}

Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M, Cho, M, Lim, HY, Chung, HC, Kim, CW, Burke, J, Lencioni, R, Hickman, T, Moon, A, Lee, YS, Kim, MK, Daneshmand, M, Dubois, K, Longpre, L, Ngo, M, Rooney, C, Bell, JC, Rhee, BG, Patt, R, Hwang, TH & Kirn, DH 2013, 'Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer', Nature Medicine, vol. 19, no. 3, pp. 329-336. https://doi.org/10.1038/nm.3089

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. / Heo, Jeong; Reid, Tony; Ruo, Leyo; Breitbach, Caroline J.; Rose, Steven; Bloomston, Mark; Cho, Mong; Lim, Ho Yeong; Chung, Hyun Cheol; Kim, Chang Won; Burke, James; Lencioni, Riccardo; Hickman, Theresa; Moon, Anne; Lee, Yeon Sook; Kim, Mi Kyeong; Daneshmand, Manijeh; Dubois, Kara; Longpre, Lara; Ngo, Minhtran; Rooney, Cliona; Bell, John C.; Rhee, Byung Geon; Patt, Richard; Hwang, Tae Ho; Kirn, David H.

In: Nature Medicine, Vol. 19, No. 3, 01.03.2013, p. 329-336.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

AU - Heo, Jeong

AU - Reid, Tony

AU - Ruo, Leyo

AU - Breitbach, Caroline J.

AU - Rose, Steven

AU - Bloomston, Mark

AU - Cho, Mong

AU - Lim, Ho Yeong

AU - Chung, Hyun Cheol

AU - Kim, Chang Won

AU - Burke, James

AU - Lencioni, Riccardo

AU - Hickman, Theresa

AU - Moon, Anne

AU - Lee, Yeon Sook

AU - Kim, Mi Kyeong

AU - Daneshmand, Manijeh

AU - Dubois, Kara

AU - Longpre, Lara

AU - Ngo, Minhtran

AU - Rooney, Cliona

AU - Bell, John C.

AU - Rhee, Byung Geon

AU - Patt, Richard

AU - Hwang, Tae Ho

AU - Kirn, David H.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in tumors, yet the impact of dose on subject outcome is unclear. JX-594 (Pexa-Vec) is an oncolytic and immunotherapeutic vaccinia virus. To determine the optimal JX-594 dose in subjects with advanced hepatocellular carcinoma (HCC), we conducted a randomized phase 2 dose-finding trial (n = 30). Radiologists infused low- or high-dose JX-594 into liver tumors (days 1, 15 and 29); infusions resulted in acute detectable intravascular JX-594 genomes. Objective intrahepatic Modified Response Evaluation Criteria in Solid Tumors (mRECIST) (15%) and Choi (62%) response rates and intrahepatic disease control (50%) were equivalent in injected and distant noninjected tumors at both doses. JX-594 replication and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression preceded the induction of anticancer immunity. In contrast to tumor response rate and immune endpoints, subject survival duration was significantly related to dose (median survival of 14.1 months compared to 6.7 months on the high and low dose, respectively; hazard ratio 0.39; P = 0.020). JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC.

AB - Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in tumors, yet the impact of dose on subject outcome is unclear. JX-594 (Pexa-Vec) is an oncolytic and immunotherapeutic vaccinia virus. To determine the optimal JX-594 dose in subjects with advanced hepatocellular carcinoma (HCC), we conducted a randomized phase 2 dose-finding trial (n = 30). Radiologists infused low- or high-dose JX-594 into liver tumors (days 1, 15 and 29); infusions resulted in acute detectable intravascular JX-594 genomes. Objective intrahepatic Modified Response Evaluation Criteria in Solid Tumors (mRECIST) (15%) and Choi (62%) response rates and intrahepatic disease control (50%) were equivalent in injected and distant noninjected tumors at both doses. JX-594 replication and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression preceded the induction of anticancer immunity. In contrast to tumor response rate and immune endpoints, subject survival duration was significantly related to dose (median survival of 14.1 months compared to 6.7 months on the high and low dose, respectively; hazard ratio 0.39; P = 0.020). JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC.

UR - http://www.scopus.com/inward/record.url?scp=84875225339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875225339&partnerID=8YFLogxK

U2 - 10.1038/nm.3089

DO - 10.1038/nm.3089

M3 - Article

C2 - 23396206

AN - SCOPUS:84875225339

VL - 19

SP - 329

EP - 336

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 3

ER -